Search - tctmd.com

Displaying 101 - 120 of 140

Sort: Relevancy | Date

News Conference News AHA 2012

AHA 2012: Multiple Studies Provide Clinical Guidance for Interventional Community

November 11, 2012

Endovascular Treatment for Infrainguinal Vessels in Patients with Critical Limb Ischemia: OLIVE Registry, a Prospective, Multicenter Study in Japan with 12-month Follow-up

Presentation AHA 2012

Endovascular Treatment for Infrainguinal Vessels in Patients with Critical Limb Ischemia: OLIVE Registry, a Prospective, Multicenter Study in Japan with 12-month Follow-up

Presenter: Masato Nakamura

November 06, 2012

News Conference News AHA 2012

RIME: Mitral Annuloplasty Plus CABG Improves Functional Capacity, Regurgitation

November 06, 2012

News Conference News AHA 2012

OLIVE: Endovascular Treatment Shows Positive Results for Critical Limb Ischemia

November 06, 2012

News Conference News AHA 2012

Evidence Continues to Support Dabigatran Treatment in A-fib

November 06, 2012

The TIME Randomized Trial: Effect of Intracoronary Delivery of Autologous Bone Marrow Mononuclear on Timing of Delivery following AMI on Left Ventricular Function

Presentation AHA 2012

The TIME Randomized Trial: Effect of Intracoronary Delivery of Autologous Bone Marrow Mononuclear on Timing of Delivery following AMI on Left Ventricular Function

Presenter: Jay H. Traverse

November 05, 2012

Intracoronary infusion of BM-MNC early or late after AMI: 4 month results of the SWISS-AMI trial

Presentation AHA 2012

Intracoronary infusion of BM-MNC early or late after AMI: 4 month results of the SWISS-AMI trial

Presenter: Daniel S?rder

November 05, 2012

News Conference News AHA 2012

No Mortality Benefit with Prolonged Dual Antiplatelet Therapy

November 05, 2012

News Conference News AHA 2012

Cell Therapy Trials Show Mixed Results at AHA 2012

November 05, 2012

News Conference News AHA 2012

ASCERT: CABG More Cost-Effective Than PCI Over Long Term

November 05, 2012

Rivaroxaban Use is Associated with Reduced Risk of Myocardial Infarction- Insights from a Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials

Presentation AHA 2012

Rivaroxaban Use is Associated with Reduced Risk of Myocardial Infarction- Insights from a Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials

Presenter: Saurav Chatterjee

November 04, 2012

Results of Exenatide Myocardial Protection In REvascularization (EMPIRE) Study

Presentation AHA 2012

Results of Exenatide Myocardial Protection In REvascularization (EMPIRE) Study

Presenter: Weon Kim

November 04, 2012

News Conference News AHA 2012

UMPIRE: Multidrug ‘Polypill’ Improves Adherence, BP, Cholesterol

November 04, 2012

News Conference News AHA 2012

Platelet Reactivity in Response to Prasugrel Depends on the Test

November 04, 2012

News Conference News AHA 2012

EMPIRE: Exenatide Cardioprotective in STEMI Patients Receiving DES

November 04, 2012

News Conference News AHA 2012

Early Study Shows Positive Clinical Results with Novel Renal Denervation Device

November 04, 2012

Presentation AHA 2012

FREEDOM Trial Main Results

Presenter: Valentin Fuster

November 04, 2012

First Large-Scale Platelet Function Evaluation in an Acute Coronary Syndromes Trial: The TRILOGY ACS — Platelet Function Substudy

Presentation AHA 2012

First Large-Scale Platelet Function Evaluation in an Acute Coronary Syndromes Trial: The TRILOGY ACS — Platelet Function Substudy

Presenter: Paul A. Gurbel

November 04, 2012

Economic Outcomes of Percutaneous Coronary Intervention Performed at Sites With and Without On-Site Cardiac Surgery

Presentation AHA 2012

Economic Outcomes of Percutaneous Coronary Intervention Performed at Sites With and Without On-Site Cardiac Surgery

Presenter: Eric L. Eisenstein

November 04, 2012

News Conference News AHA 2012

TRILOGY ACS Substudy: No Relationship Between Platelet Reactivity, Outcomes

November 04, 2012

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.